Steris: Marginal Gains Capitalized At Higher Rates, Reiterate Buy
STERIS remains a high-quality, defensive cash recycler with diversified growth, expanding margins, strong cash conversion, and disciplined capital deployment. Q1 FY'26 results showed broad-based 9% revenue growth, margin expansion across all segments, and raised full-year guidance, supporting my positive investment view. Valuation is fair with upside to $270–$300/share; the company excels at recycling cash into earnings, dividends, and buybacks, despite modest top-line growth.
Here's Why Steris (STE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Understanding Steris (STE) Reliance on International Revenue
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
STERIS plc (STE) Q1 2026 Earnings Call Transcript
STERIS plc (NYSE:STE ) Q1 2026 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel A. Carestio - President, CEO & Director Julie Winter - Vice President of Investor Relations & Corporate Communications Michael J.
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.
Compared to Estimates, Steris (STE) Q1 Earnings: A Look at Key Metrics
The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Steris (STE) Tops Q1 Earnings and Revenue Estimates
Steris (STE) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.03 per share a year ago.
Steris (STE) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Steris (STE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
Steris (STE) Earnings Expected to Grow: Should You Buy?
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Loses 6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Steris (STE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
